Research Paper Volume 15, Issue 6 pp 2136—2157

Figure 1. Basic information for CDKN2A. (A) The expression level of CDKN2A between tumor and normal tissue of each cancer based on the integration of data from the TCGA and GTEx datasets. (B)The CDKN2A expression in LGG and normal brain tissue. (C) The western blot assay showed the gray gels of proteins of LGG and adjacent tissues. (D) Quantitative analysis showed the upregulation of CDKN2A in LGG samples compared with adjacent tissues. (E) Analysis of the frequency of CDKN2A changes in pan-cancer studies based on the cBioPortal database. (F) CDKN2A expression levels and DFS prognosis in GBM patients with CDKN2A altered and unaltered. (G) Pan-cancer survival of CDKN2A. (H) Immunofluorescence images and fusion images of CDKN2A protein in nuclei, endoplasmic reticulum, and microtubules in A-431 and U251 cell lines. (I) The protein-protein interaction (PPI) network presents a protein interacting with CDKN2A. Asterisks indicate statistical p-values (ns p>0.05, *p<0.05, **p<0.01, and ***p<0.001).